Market Size of Europe Sodium-dependent Glucose Cotransporter 2 Industry
Study Period | 2018 - 2029 |
Base Year For Estimation | 2023 |
Market Size (2024) | USD 1.30 Billion |
Market Size (2029) | USD 2.02 Billion |
CAGR (2024 - 2029) | 9.10 % |
Market Concentration | High |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Sodium-dependent Glucose Cotransporter 2 Market Analysis
The Europe Sodium-dependent Glucose Cotransporter 2 Market size is estimated at USD 1.30 billion in 2024, and is expected to reach USD 2.02 billion by 2029, growing at a CAGR of 9.10% during the forecast period (2024-2029).
The European region had witnessed an alarming increase in the prevalence of diabetes, in recent years. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as medications or ingestion of additional carbohydrates by monitoring their blood glucose levels.
The disease's growing incidence, prevalence, and progressive nature encouraged the development of new drugs to provide additional treatment options for diabetic patients. Non-insulin treatments, used as first-line therapies for patients with type 2 diabetes, currently capture more than half the sales in the anti-diabetic market. Over the past decade, two important classes entered this market: dipeptidyl peptidase-4 inhibitors (DPP-4) and sodium-glucose cotransporter-2 inhibitors (SGLT-2). These agents work in various ways to reduce blood sugar levels in people with type 2 diabetes. Some stimulate insulin secretion by the pancreas, and others improve the responsiveness of cells to insulin or prevent glucose production by the liver. Others slow the absorption of glucose after meals.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.